Ann: 1st patient dosed in CHM 0201 Vactosertib trial, page-14

Our CHM 0201 Vactosertib trial is recruiting again:
https://clinicaltrials.gov/study/NCT05400122?tab=table

And our new COO will be presenting at the Bio International Convention on in San Diego next month (5th June):
https://convention.bio.org/sessions/chimeric-therapeutics

Maybe we will get an update on CHM 2101 (CDH17) by then which is "scheduled to open in mid-2024."

As to the upcoming dilution, well, we all knew that money will be needed and after the last two rounds in short succession, the company had to go for a different approach. While we always hope for a partnership or licensing deal when it comes to funding, early stage biotech "surprises" you 9 times out of 10 with a Cap Raise or any other shape or form of dilution. But that 1 time out of 10, that's what we are all hoping for here given our current MC compared to other biotech companies in this space. Even the dilution won't stop this from taking off if our clinical data holds up.